Early Renal Benefit of Rapamycin Combined With Reduced Calcineurin Inhibitor Dose in Pediatric Heart Transplantation Patients

Journal of Heart and Lung Transplantation

Volumn 25, Issue 5, 2006, Pages 518-522

  Balfour, Ian C ^a   Srun, Sopheak W ^a   Wood, Ellen G ^b   Belsha, Craig W ^b   Marshall, Donna L ^a   Ferdman, Barbara R ^c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; LIPID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ARTICLE; BIOPSY; CHILD; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LYMPHOPROLIFERATIVE DISEASE; MOUTH ULCER; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

BLOOD UREA NITROGEN; CALCINEURIN; CHILD; CHILD, PRESCHOOL; CREATININE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY; KIDNEY FUNCTION TESTS; MALE; PLATELET COUNT; RETROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS;

EID: 33646138493     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2006.01.004     Document Type: Article

References (17)

1. Halloran P.F., and Miller L.W. In vivo immunosuppressive mechanisms. J Heart Lung Transplant 15 (1996) 959-971
2. Pietra B.A., and Boucek M.M. Immunosuppression for pediatric cardiac transplantation in the modern era. Prog Pediatr Cardiol 11 (2000) 115-129
3. Davies D., Bittmann I., and Pardo J. Histopathology of calcineurin inhibitor-induced nephrotoxicity. Transplantation 69 12 Suppl (2000) SS11
4. Goldstein D.J., Zuech N., Sehgal V., et al. Cyclosporine-associated end stage nephropathy after cardiac transplantation. incidence and prognosis. Transplantation 63 (1997) 664-668
5. Sindhi R. Sirolimus in pediatric transplant recipients. Transplant Proc 35 Suppl 3A (2003) 113S-114S
6. Sindhi R., Webber S., Venkataramanan R., et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 72 (2001) 851-855
7. MacDonald A.S. Management strategies for nephrotoxicity. Transplantation 69 (2000) 5531-5536
8. Schwartz G.J., Haycock G.B., Edelmann Jr. C.M., and Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58 (1976) 259-263
9. Sehgal S.N. Rapamune. mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 31 (1998) 335-339
10. Groetzner J., Meiser B., Landwehr P., et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac transplant recipients with chronic renal failure. Transplantation 77 (2004) 568-573
11. Trosch F., Rothenburger M., Schneider M., Welp H., Etz C., and Wilhelm M. First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation. Thorac Cardiovasc Surg 52 (2004) 163-168
12. Snell G.I., Levvey B.J., Chin W., et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal failure. J Heart Lung Transplant 21 (2002) 510-546
13. Lobach N.E., Pollock-Barziv S.M., West L.J., and Dipchand A.I. Sirolimus immunosuppression in pediatric heart transplant recipients. a single center experience. J Heart Lung Transplant 24 (2005) 184-189
14. Mancini D., Pinney S., Burkhoff D., et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 108 (2003) 48-53
15. Murgia M.G., Jordan S., and Kahan B.D. The side effect profile of sirolimus. a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 49 (1996) 209-216
16. McOmber D., Ibrahim J., Lublin D.M., et al. Non-ischemic left ventricular dysfunction after pediatric cardiac transplantation. Treatment with plasmapheresis and OKT3. J Heart Lung Transplant 23 (2004) 552-557
17. Webber S.A., Naftel D.C., Parker J., et al. Late rejection episodes more than 1 year after pediatric heart transplantation. Risk factors and outcomes. J Heart Lung Transplant 22 (2003) 869-875